According to TipRanks, Sergott is an analyst with an average return of -7.8% and a 32.04% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Sotera Health, PerkinElmer, and IQVIA Holdings.
Currently, the analyst consensus on Twist Bioscience is a Moderate Buy with an average price target of $48.00, implying a 93.47% upside from current levels. In a report released on November 15, Robert W. Baird also maintained a Buy rating on the stock with a $56.00 price target.
TWST market cap is currently $1.4B and has a P/E ratio of -6.27.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The company also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. Twist Bioscience was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.
Read More on TWST: